These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3345487)

  • 1. Effects of tamoxifen on blood coagulation.
    Auger MJ; Mackie MJ
    Cancer; 1988 Apr; 61(7):1316-9. PubMed ID: 3345487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monocyte procoagulant activity in breast cancer.
    Auger MJ; Mackie MJ
    Thromb Res; 1987 Jul; 47(1):77-84. PubMed ID: 3660345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of tamoxifen on plasma coagulation and serous fibrinolysis.
    Jankowski J; Ramlau C; Kopczynski Z; Boryska M
    Eur J Gynaecol Oncol; 1993; 14 Suppl():155-8. PubMed ID: 8200368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels.
    Bertelli G; Pronzato P; Amoroso D; Cusimano MP; Conte PF; Montagna G; Bertolini S; Rosso R
    Breast Cancer Res Treat; 1988 Dec; 12(3):307-10. PubMed ID: 3228593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen treatment of metastatic breast cancer and antithrombin III levels.
    Enck RE; Rios CN
    Cancer; 1984 Jun; 53(12):2607-9. PubMed ID: 6426771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tamoxifen on measurements of hemostasis in healthy women.
    Mannucci PM; Bettega D; Chantarangkul V; Tripodi A; Sacchini V; Veronesi U
    Arch Intern Med; 1996 Sep; 156(16):1806-10. PubMed ID: 8790074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chemoendocrine therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer. Japan Advanced Breast Cancer Study Group and Japan Clinical Oncology Group.
    ;
    Jpn J Cancer Res; 1993 Apr; 84(4):455-61. PubMed ID: 8514613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer.
    von Tempelhoff GF; Dietrich M; Hommel G; Heilmann L
    J Clin Oncol; 1996 Sep; 14(9):2560-8. PubMed ID: 8823336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III.
    Jordan VC; Fritz NF; Tormey DC
    Cancer Res; 1987 Aug; 47(16):4517-9. PubMed ID: 3607780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects on blood coagulation of adjuvant CNF (cyclophosphamide, novantrone, 5-fluorouracil) chemotherapy in stage II breast cancer patients.
    Pectasides D; Tsavdaridis D; Aggouridaki C; Tsavdaridou V; Visvikis A; Tsatalas K; Fountzilas G
    Anticancer Res; 1999; 19(4C):3521-6. PubMed ID: 10629646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tamoxifen on lipid profile and coagulation parameters in male patients with pubertal gynecomastia.
    Nóvoa FJ; Boronat M; Carrillo A; Tapia M; Díaz-Cremades J; Chirino R
    Horm Res; 2002; 57(5-6):187-91. PubMed ID: 12053091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodialysis with defibrotide: effects on coagulation parameters.
    Filimberti E; Cinotti S; Salvadori M; Amato M; Longo G; Nazzari M; Morfini M
    Int J Artif Organs; 1992 Oct; 15(10):590-4. PubMed ID: 1428206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy.
    Love RR; Surawicz TS; Williams EC
    Arch Intern Med; 1992 Feb; 152(2):317-20. PubMed ID: 1739360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the plasma coagulation system induced by some biomaterials.
    Cenni E; Ciapetti G; Cervellati M; Cavedagna D; Falsone G; Gamberini S; Pizzoferrato A
    J Biomed Mater Res; 1996 May; 31(1):145-8. PubMed ID: 8731159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.
    Jones AL; Powles TJ; Treleaven JG; Burman JF; Nicolson MC; Chung HI; Ashley SE
    Br J Cancer; 1992 Oct; 66(4):744-7. PubMed ID: 1419616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of tamoxifen and estrogen replacement therapy on lipid metabolism and some other cardiovascular risk factors. A prospective study in hysterectomised women].
    Imperato F; Marziani R; Perniola G; Ebano V; Fruscella M; Mossa B
    Minerva Ginecol; 2003 Feb; 55(1):87-93. PubMed ID: 12598849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Coagulation inhibitors in patients with neoplasms].
    Páramo JA; Cuesta B; Hernández M; Fernández J; Paloma MJ; Rifón J; Rocha E
    Med Clin (Barc); 1989 Feb; 92(5):164-6. PubMed ID: 2524631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemostatic alterations caused by ventricular assist devices for postcardiotomy heart failure.
    Tanaka K; Wada K; Morimoto T; Shomura S; Nasu M; Okada Y; Yada I; Yuasa H; Kusagawa M
    Artif Organs; 1991 Feb; 15(1):59-65. PubMed ID: 1998493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of combined tamoxifen and medroxyprogesterone treatment on coagulation-fibrinolytic systems in patients with advanced breast cancer.
    Fukutomi T; Adachi I; Watanabe T; Nanasawa T; Yamamoto H
    Acta Oncol; 1993; 32(5):573-4. PubMed ID: 8217244
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.